Isitofu seRanitidine

Inkcazelo emfutshane:

· Ixabiso & Ikoteshini: FOB Shanghai: Thetha ngoMntu · IPort yoThutho: Shanghai, Tianjin, Guangzhou, Qingdao · MOQ(50mg,2ml):300000amps · Imigaqo yeNtlawulo: T/T, L/C Iinkcukacha zeMveliso Ukuqulunqwa ...

  • : IRanitidine ifunxwa ngokukhawuleza emva kwesitofu se-intramuscular kwaye ine-bioavailability emalunga nama-90 ukuya kwi-100%.Ukupheliswa kobomi besiqingatha kwi-plasma malunga ne-2 ukuya kwiiyure ze-3 kwaye i-ranitidine ibotshwe buthathaka malunga ne-15%, kwiiprotheni ze-plasma.
  • Iinkcukacha zeMveliso

    Iithegi zeMveliso

    ·Ixabiso kunye neNtelekelelo:FOB Shanghai: Xoxa ngoMntu

    ·Indawo yokuthumela ngenqanawa: eShanghai, eTianjin,eGuangzhou, eQingdao

    ·MOQ(50mg,2ml):300000amps

    ·Immimiselo yokuhlawula:T/T, L/C

    Iinkcukacha zemveliso

    Ukuqamba
    I-ampoule ye-ranitidine iqukethe i-rannitidine hydrochloride USP XXIII 50 mg.
    Isalathiso
    I-Ranitidine yi-histamine H2-receptor antagonist, Ngokuhambelanayo, inqanda ukukhutshwa kwe-asidi yesisu kunye nokunciphisa imveliso ye-pepsin: ibonakaliswe ukuba inqanda ezinye izenzo ze-histamine ezixutywe yi-H2-receptors, Isetyenziselwa ukulawula izifo ezahlukeneyo zesisu. njenge-aspiration syndromes, i-dyspepsia, isifo se-reflux ye-gastro-oesophageal, isilonda se-peptic kunye nesifo se-Zollinger-Ellison.

    Ukhuseleko

    Ngaphambi kokunika i-ranitidine kwizigulana ezinezilonda ze-gastrle, amathuba okuba nobungozi kufuneka akhutshelwe ngaphandle kuba i-ranitidine inokufihla iimpawu kunye nokulibazisa ukuxilongwa.Kufuneka inikwe kwidosi encitshisiweyo kwizigulane ezinokukhubazeka komsebenzi wezintso.

    Imiphumo emibi

    Ezona ziphumo bezingalindelekanga zixhaphakile eziye zaxelwa burhudo, isiyezi, intloko ebuhlungu, kunye nerhashalala.Ezinye iziphumo ezibi, eziye zaxelwa ngokunqabileyo, ziimpendulo ze-hypersensilivity kunye nomkhuhlane, i-arthralgia kunye ne-myalgia.Iziphazamiso zegazi ezibandakanya i-agranulocytosis okanye i-neutropenia kunye ne-thrombocytopenia, i-hepatotoxicity, i-hepatotoxicity , kunye nokuphazamiseka kwentliziyo, nangona kunjalo, ngokungafaniyo ne-cimetidine, i-ranitidine inempembelelo encinci okanye ayikho i-anti-andiogenic, nangona kukho iingxelo ezizimeleyo ze-gyhaecomaslia kunye nokungabi namandla.

    Umthamo kunye noLawulo
    Ngokuxhomekeke kwimeko ephathwa ngayo idosi eqhelekileyo nge-intramuscular or intravenous injection yi-50 mg, enokuthi iphindwe rhoqo kwii-6 kwiiyure ze-8: i-injection ye-inravenous kufuneka inikwe ngokukhawuleza ngaphantsi kwemizuzu ye-2 kwaye kufuneka ihlanjululwe ukuze iqulethe i-50 mg I-20ml ye-intermittent intravenous infusion i-dose ekhuthazwayo e-UK yi-25 mg ngeyure enikwe i-2hours enokuthi iphindwe rhoqo kwi-6 kwiiyure ze-8 izinga le-6.25mg ngeyure liye lacetyiswa ukuba liqhube ngokungena kwi-intravenous nangona amazinga aphezulu angaqeshwa. iimeko ezifana neZollinger-Ellison syndrome okanye kwizigulane ezisengozini yoxinzelelo loxinzelelo.

    Ukugcinwa kunye nexesha eliphelelwe lixesha
    Gcinangaphantsi kwe25℃.
    3 iminyaka
    Ukupakisha

    2ml*10amps
    Ukugxila
    50mg

     


  • Ngaphambili:
  • Okulandelayo: